Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shanghai Shenqi Pharmaceutical Investment Management Co Buyback Yield % Chart
Shanghai Shenqi Pharmaceutical Investment Management Co Annual Data
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shanghai Shenqi Pharmaceutical Investment Management Co Buyback Yield % vs Drug Manufacturers Industry
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shanghai Shenqi Pharmaceutical Investment Management Co (SHSE:600613) has a Buyback Yield % of 0.00 as of Jul. 15, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Shanghai Shenqi Pharmaceutical Investment Management Co and its competitors. According to the industry distribution chart, Shanghai Shenqi Pharmaceutical Investment Management Co ranks #999999 out of 290 companies in the Drug Manufacturers industry.
Is Shanghai Shenqi Pharmaceutical Investment Management Co's Buyback Yield % too high?
Shanghai Shenqi Pharmaceutical Investment Management Co's current Buyback Yield % is 0.00. Based on the distribution chart, Shanghai Shenqi Pharmaceutical Investment Management Co ranks #999999 out of 290 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Shanghai Shenqi Pharmaceutical Investment Management Co has a GF Score™ of 53/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Shanghai Shenqi Pharmaceutical Investment Management Co's Buyback Yield % compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Shanghai Shenqi Pharmaceutical Investment Management Co ranks #999999 out of 290 companies for Buyback Yield %. This places Shanghai Shenqi Pharmaceutical Investment Management Co in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Drug Manufacturers company?
A good Buyback Yield % depends on the Drug Manufacturers industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Shanghai Shenqi Pharmaceutical Investment Management Co and its competitors. Shanghai Shenqi Pharmaceutical Investment Management Co's current Buyback Yield % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shanghai Shenqi Pharmaceutical Investment Management Co stock overvalued right now?
Based on GuruFocus' analysis, Shanghai Shenqi Pharmaceutical Investment Management Co (SHSE:600613) is currently considered Fairly Valued. The stock's GF Value™ is ¥5.43, compared to a current price of ¥5.11 — trading 5.9% below its estimated fair value. The current Buyback Yield % is 0.00. Shanghai Shenqi Pharmaceutical Investment Management Co's overall GF Score™ is 53/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Shanghai Shenqi Pharmaceutical Investment Management Co (SHSE:600613), the current Buyback Yield % is 0.00 as of Jul. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shanghai Shenqi Pharmaceutical Investment Management Co (SHSE:600613) Overvalued in 2026?
Based on GuruFocus' analysis, Shanghai Shenqi Pharmaceutical Investment Management Co stock appears to be undervalued.
The current stock price of ¥5.11 is trading 5.9% below its estimated GF Value™ of ¥5.43.
GuruFocus considers Shanghai Shenqi Pharmaceutical Investment Management Co to be Fairly Valued.
Key valuation signals for SHSE:600613:
Buyback Yield %: 0.00
GF Value™: ¥5.43 vs. price of ¥5.11 (5.9% below fair value)
No single metric tells the full story. See the SHSE:600613 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shanghai Shenqi Pharmaceutical Investment Management Co Business Description
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600613 has been successfully added to your 
